Health Economics›Chronic myeloid leukemia›Accelerated phase previously treated

Accelerated phase previously treated

Chronic myeloid leukemia · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Nilotinib monotherapy Variant #01	—	R 27 206	28d	—	—	—	—	—
Dasatinib monotherapy Variant #01	—	R 12 899	28d	—	—	—	—	—
Omacetaxine monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Olverembatinib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Ponatinib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

5 of 5 regimens shown